Back

Alirocumab and cardiovascular outcomes in patients without a prior ischemic event

29 August 2026 (14:40 - 14:50)
Organised by: Logo
Congress Presentation Part of: Lipid lowering in the prevention era: from statins to RNA therapeutics Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Maarten Leening

Erasmus MC - University Medical Center Rotterdam, Rotterdam (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
The clinical benefits of immediate versus delayed use of PCSK9 inhibitors for patients with established atherosclerotic cardiovascular disease in the UK
Professor K. Ray (London, GB)
Abstract
Presentation thumbnail
Potent and sustained blood pressure reduction with a novel small interfering RNA targeting hepatic angiotensinogen: results from a first-in-human, randomised, phase 1 study
Doctor M. Yang (Chengdu, CN)
Abstract
Presentation thumbnail
Real-world comparative outcomes of evolocumab versus high-intensity statin for primary prevention
Doctor A. Ajibade (Iowa City, US)
Abstract
Presentation thumbnail
Reduction in total cardiovascular events with evolocumab in patients with no prior myocardial infarction or stroke: a pre-specified analysis of VESALIUS-CV
Professor J. Nicolau (Sao Paulo, BR)
Abstract
Presentation thumbnail
Association of cancer incidence and cancer mortality with statins, ezetimibe, and statin–ezetimibe therapy: a pairwise and bayesian network meta-analysis of randomized controlled trials
Doctor S. Saluja (New Delhi, IN)
Abstract

Access the full session

Session thumbnail
Lipid lowering in the prevention era: from statins to RNA therapeutics

The Event

Event poster

ESC Congress 2026

29 August 2026 14:40 CET
You may be interested in
thumbnail
Congress Presentation
Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment
2 September 2019
thumbnail
Congress Presentation
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study
30 August 2020
thumbnail
Congress Presentation
Pleiotropic effects of inclisiran on arterial structural and functional parameters
4 April 2025
thumbnail
Congress Presentation
Reduction of cardiovascular events in patients with cardiovascular disease with the CV-polypill: a retrospective and propensity score matching study
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources